# Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5)

> **NCT06492564** · EARLY_PHASE1 · COMPLETED · sponsor: **Hvivo** · enrollment: 36 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 omicron virus dose arm 1
- **BIOLOGICAL:** SARS-CoV-2 omicron virus dose arm 2
- **BIOLOGICAL:** SARS-CoV-2 omicron virus dose arm 3

## Key facts

- **NCT ID:** NCT06492564
- **Lead sponsor:** Hvivo
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-02
- **Primary completion:** 2025-10-16
- **Final completion:** 2025-10-16
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06492564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06492564, "Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06492564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*